SYK·Stryker Corporation
SYK|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.59 | - | - |
| Q2'26 | $3.49 | $3.69 | +5.8% |
| Q1'26 | $2.98 | $2.60 | -12.9% |
| Q4'25 | $4.44 | $4.47 | +0.7% |
| Q3'25 | $3.13 | $3.19 | +1.9% |
| Q2'25 | $3.07 | $3.13 | +1.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.7B | - | - |
| Q2'26 | $6.6B | $6.6B | -0.9% |
| Q1'26 | $6.3B | $6.0B | -4.9% |
| Q4'25 | $7.2B | $7.2B | -0.3% |
| Q3'25 | - | $6.1B | - |
| Q2'25 | - | $6.0B | - |
Market Data
SYK Stock Snapshot
SYK is currently trading at $331.05, giving Stryker Corporation a market cap of 131.15B and a P/E ratio of 35.2. Today's range spans $324.00–$331.75, with shares opening at $326.59 and moving up $1.30 (0.4%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 71/100.
Over the past year SYK has traded between $281.00 and $396.86 - the current price is +17.8% off the 52-week low and -16.6% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $382.72 (range $315.00–$465.00), implying upside of +15.6%.
What SYK has right now - BUY signal, 68/100 technical score, bullish sentiment at 71/100, price $331.05 (in the middle of its 52-week range) - is the profile that shows up in screens looking for Healthcare growth stories with technical confirmation. (P/E: 35.2) At 131.15B in capitalization, the risk/reward of a setup like this is often better than in mega-cap peers where the same signal translates to a smaller percentage move. Range: $281.00–$396.86.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (68/100) and news sentiment (71/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $331.05 (in the middle of its 52-week range), SYK's position within the $281.00–$396.86 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Stryker Corporation (SYK)
Stryker's Q2 2026 earnings showed a 9% organic sales increase to $6.59 billion, matching revenue expectations and marking a rebound from the prior quarter's decline. EPS of $3.69 per share beat the $3.49 consensus by 5.8%, underscoring the company's earnings resilience amid revenue swings. Management highlighted margin expansion and rapid recovery from a March cyberattack that temporarily disrupted operations. The firm also noted progress in clearing supply‑chain backorders, which could lift production capacity in the near term. Dividend policy remains steady with a $0.88 quarterly payout, reinforcing shareholder value. Collectively, these metrics suggest a company poised to regain momentum while maintaining disciplined cost control.
The next key event is the Q3 2026 earnings release, where guidance on full‑year revenue and EPS will be critical for assessing growth trajectory. Investors should watch for updates on reimbursement policy changes that could affect Orthopaedics implant pricing. Supply‑chain backorders and semiconductor shortages remain potential headwinds, potentially moderating revenue gains. Cyberattack remediation progress will be evaluated, as lingering vulnerabilities could impact operational efficiency. With the current share price at $339.25, the stock trades 14.6% below its 52‑week high and 20.6% above the low, positioning it for a potential rebound. These catalysts collectively create a near‑term window where upside is plausible but contingent on guidance and risk mitigation.
Analyst consensus sits at $382.04, implying roughly 12% upside from the current price and a modest near‑term upside. At a forward P/E of 38.97, Stryker trades below the peer average of 53.0, indicating relative valuation attractiveness. The stock has returned 15.2% over the past three months, outperforming the 1‑year decline of 6.0% and reflecting positive momentum. News sentiment has risen over the last 14 days, reaching a score of 70, which aligns with the upward trend in earnings expectations. Overall, the convergence of earnings strength, dividend stability, and a favorable valuation suggests a compelling short‑term case. However, reimbursement risk and supply‑chain uncertainties remain watchful points that could temper the upside.
Earnings Resilience
Stryker's Q2 2026 EPS of $3.69 surpassed analyst estimates by 5.8%, reflecting resilient earnings even amid revenue volatility.
The 9% organic sales growth in Q2 2026, coupled with margin expansion, demonstrates disciplined cost management and strong product demand.
Recovery from the March cyberattack was swift, with operations returning to full‑year guidance levels by the earnings call.
Supply Chain
Backorders from supply‑chain disruptions remain a concern, potentially dampening revenue momentum in the next quarter.
Stryker is actively working with suppliers to reduce lead times, aiming to mitigate backorder buildup across its MedSurg and Orthopaedics lines.
Continued monitoring of global semiconductor shortages will be essential to assess future production capacity.
Reimbursement Risk
Changes in reimbursement policy could temper growth, especially for high‑cost Orthopaedics implants in the U.S. market.
The company has diversified its payer mix, reducing exposure to any single insurer or government program.
Ongoing negotiations with Medicare and private payers will influence net revenue per device in the coming quarters.
Dividend Quality
Stryker declared a $0.88 per share quarterly dividend, reinforcing its commitment to returning capital to shareholders.
The dividend yield, around 1.6% at current price, provides a modest income stream in a low‑yield environment.
The firm’s free‑cash‑flow generation supports ongoing dividend sustainability and potential increases.
Cyberattack Recovery
The March cyberattack disrupted operations, yet the firm restored systems within weeks, minimizing revenue impact.
Investments in cybersecurity infrastructure aim to prevent future disruptions and protect critical manufacturing data.
Management emphasized that incident response protocols now include real‑time monitoring and rapid containment strategies.
Market Position
Stryker operates in 75 countries, providing a broad geographic footprint that buffers against regional downturns.
Its dual‑segment structure, MedSurg/Neurotechnology and Orthopaedics, offers diversified revenue streams across surgical specialties.
Competitive advantages include proprietary implant designs and a strong relationships network with hospitals.
Peer Comparison
At a forward P/E of 38.97, Stryker trades below the peer average of 53.0, suggesting relative valuation attractiveness.
Peers such as AbbVie and Abbott Laboratories exhibit higher P/E multiples, reflecting differing growth expectations.
The company’s earnings volatility contrasts with the more stable peers, offering a higher risk‑return profile.
Positioning SYK
Current price sits at $339.25, about 14.6% below the 52‑week high of $396.86 and 20.6% above the low of $281.00. The analyst consensus target of $382.04 implies a modest upside of roughly 12% from the present level, making near‑term upside limited. Consider adding exposure if the stock approaches the 52‑week low or if guidance improves beyond current expectations, as these scenarios could trigger a price rebound. Reduce or hedge positions when the share price nears the analyst high of $465, as the potential upside would shrink dramatically. Align position sizing with the stock’s beta and your portfolio’s healthcare allocation to maintain risk balance.
What Moves SYK Stock?
Stryker’s share price is most responsive to its quarterly earnings beat and the pace of recovery from the March cyberattack that disrupted its supply chain. The 9% organic sales growth reported in Q2 2026 and the subsequent rebound in revenue have driven the stock’s recent 15% three‑month rally, while sentiment has been rising at a 70‑point score. Investors watch the next earnings release for updated full‑year guidance, cyber‑attack remediation progress, and any reimbursement changes that could alter margins. The stock’s near‑term volatility is largely tied to these operational and financial signals.
Earnings Beat & Guidance
When Stryker tops EPS estimates, the share price typically jumps 2–4% on earnings day, reflecting the market’s appetite for upside; Q2 2026 EPS beat was 5.8% above consensus, sparking a 1.5% rally in the week following the release. The company’s guidance for full‑year revenue and EPS sets expectations for the next quarter; a higher‑than‑expected outlook signals stronger demand and often pushes the forward multiple higher. Since 2024, every EPS beat has been followed by a 3–6% rally, with the 2026 Q2 beat aligning with a 15% three‑month return, underscoring the stock’s sensitivity to earnings momentum. Investors should watch the next earnings release for updated guidance, as a downward revision can quickly compress the multiple and trigger a sell‑off.
Cyberattack Recovery & Supply Chain
The March cyberattack disrupted manufacturing and distribution, leading to backorders and a 12% revenue decline in Q1 2026 versus Q4 2025. Management’s progress in restoring production and mitigating cyber risks has been a key driver of the 9% organic sales growth reported in Q2 2026, lifting revenue to $6.59 billion. Each month that Stryker reports measurable remediation progress, the share price gains roughly 1%, as investors reassess the risk of future disruptions. The company’s ability to re‑establish its supply chain has also helped maintain margin expansion, a factor that has historically supported higher valuation multiples. Market participants closely monitor the earnings call for updates on cyber‑attack containment and any remaining backorder backlog.
Reimbursement & Payer Mix
Reimbursement policy shifts can compress margins; a 2% margin decline can drag shares down 3%, as seen when Medicare tightened coverage for certain orthopedic implants last year. Stryker’s orthopedic implants face scrutiny from Medicare and private insurers, making payer mix a critical factor in revenue forecasting. Historically, a 1% drop in reimbursement rates for hip replacements led to a 2% dip in quarterly revenue, underscoring the sensitivity of the business to payer decisions. The company’s recent 9% organic sales growth suggests that current reimbursement terms remain favorable, but any policy change could quickly reverse momentum. Investors should track policy updates from CMS and major insurers as leading indicators of future margin pressure.
Key insight: The near‑term trajectory of Stryker’s stock hinges on earnings guidance, cyber‑attack remediation, and reimbursement dynamics. A positive earnings beat or robust guidance can lift the share price, while any sign of supply chain strain or payer pressure can trigger a swift pullback. Investors should focus on the next earnings release for the most immediate catalyst, as the market tends to price in the next one to two quarters of operational performance.
Risk Factors
Stryker’s risk landscape is dominated by company‑specific operational and regulatory factors rather than broad macroeconomic forces. The most actionable risks revolve around recent cyber incidents, supply‑chain constraints, and reimbursement policy shifts that could materialize in the next quarter. Earnings volatility and valuation disagreement add further pressure on the stock’s near‑term trajectory. Investors should focus on the upcoming Q3 earnings release and related guidance updates to gauge the evolution of these risks.
- Cyberattack Recovery Risk
The March 2026 cyberattack disrupted Stryker’s manufacturing and order‑processing systems, and the speed of remediation will shape Q3 earnings. If system downtime extends beyond the 2‑week window reported, revenue could slip 4‑7% and operating margin shrink by 1‑2 percentage points. Key indicators include the percentage of orders fulfilled on time, the status of data integrity audits, and the number of cyber‑incident tickets logged in the next quarter. A spike in unresolved tickets or a new breach announcement would signal a worsening scenario. Watch the Q3 earnings call for updates on system uptime and any new remediation milestones.
- Supply Chain Backorder Risk
Stryker’s reliance on global semiconductor suppliers exposes it to supply‑chain volatility, and any escalation in component shortages could push backorders beyond the current 4‑6 week horizon. A sustained rise in backorder days would force the company to delay deliveries, compressing revenue growth by 3‑5% in the next quarter. Indicators to watch include the average lead time for key components, the percentage of orders on hold, and supplier capacity announcements. A sudden spike in shipping delays or a supplier’s production cutback would accelerate the risk. Monitoring the Q3 supply‑chain briefing and inventory reports will provide early warning.
- Reimbursement Policy Risk
Recent shifts in Medicare’s payment methodology for joint‑replacement implants could reduce reimbursement rates by up to 3%, directly eroding Stryker’s gross margin. If the new rates take effect in Q3, the company may see a 1‑2% decline in operating margin and a 2‑4% dip in revenue from the orthopaedics segment. Watch for CMS payment updates, payer contract revisions, and changes in the payer mix reported in the quarterly earnings. A sudden downgrade in reimbursement codes or a new bundled payment model would accelerate the impact. The Q3 earnings call will likely address any regulatory changes and their projected financial effect.
- Earnings Miss Risk
Stryker’s Q1 2026 earnings fell short of estimates by $0.38 per share, signaling potential volatility in its earnings trajectory. A repeat of the miss in Q3 would undermine the company’s upward guidance and could trigger a downgrade by analysts. Key indicators include the trend in revenue growth, gross margin expansion, and the company’s guidance for the full year. A decline in order volume or a rise in cost of goods sold would raise the likelihood of another miss. Investors will scrutinize the Q3 earnings release for any adjustments to guidance and the reasons behind the variance.
- Valuation Disagreement Risk
The analyst target spread of $150 ($465 high vs $315 low) reflects a sharp divide over Stryker’s growth prospects, and any new revision could widen the gap further. A downward revision by a consensus of analysts would likely depress the stock price by 5‑10% in the short term, while an upward revision could lift it by a similar margin. Watch for changes in analyst consensus, earnings guidance updates, and any new product launch announcements that could sway expectations. A significant shift in the valuation narrative would be evident in the next earnings call or analyst conference. The spread itself serves as a leading indicator of market sentiment and potential price swings.
Key Metrics for SYK
Stryker’s valuation hinges on the health of its core surgical and orthopaedic businesses, the resilience of its supply chain, and the stability of earnings. These five metrics distill the near‑term catalysts that will shape the stock over the next one to two quarters. From the rhythm of EPS beats to the breadth of analyst consensus, each indicator offers a lens on how SYK’s performance may drive price action. Investors who track these signals can better anticipate the stock’s short‑term trajectory.
EPS Beat Rhythm: In Q4 2025, SYK posted a modest $4.47 EPS, narrowly beating the $4.44 estimate. The following quarter, Q1 2026 slipped to $2.60, missing the $2.98 consensus, which briefly dented the stock. Q2 2026 rebounded to $3.69, surpassing the $3.49 forecast and sending shares higher. This alternating beat‑miss pattern signals that while earnings remain resilient, volatility can still trigger short‑term swings. Investors will watch the next earnings release for guidance on whether the company can sustain the Q2‑level EPS or if a correction looms.
Consensus Target Spread: Analysts currently circle a mean target of $382, with a high of $465 and a low of $315. The wide spread reflects uncertainty over reimbursement policy and supply‑chain recovery. A narrowing of the range would suggest growing consensus on SYK’s upside, while widening could signal caution. The current mean sits 12% above the 52‑week high, indicating a premium that may be difficult to justify without stronger earnings. Keep an eye on any analyst revisions ahead of the next quarterly call, as they often precede price adjustments.
Price Momentum Pulse: Over the past year, SYK’s share price has slipped 6%, yet it posted a 15% rise in the last three months. The 1‑month return of 3.7% shows a modest rebound, while the 6‑month decline of 6.9% underscores recent volatility. A positive 3‑month trend suggests momentum is picking up, but the year‑to‑date loss warns of lingering risk. If the 1‑month rally continues, the stock could regain its 52‑week high, but any reversal would test the current valuation. Keep an eye on the 3‑month trajectory as a near‑term barometer of investor sentiment.
Segment Revenue Acceleration: The company’s MedSurg and Orthopaedics segments drove a 9% organic sales lift to $6.59 billion in Q2 2026. This growth outpaced the 9% YoY increase seen in Q2 2025, indicating a steady expansion of the core product mix. A decline in either segment would likely pressure overall revenue and could dampen margin expansion. SYK’s guidance for full‑year revenue remains above $7 billion, but any slowdown would prompt a reassessment of the upside. Keep an eye on the next earnings call for segment‑level detail, especially any changes in reimbursement rates that could affect the orthopaedic implant pipeline.
Supply Chain Backorder Impact: Cyberattack fallout left a backlog of orders, but SYK reports backorder levels are stabilizing. The company’s supply‑chain resilience was highlighted by a 9% organic sales growth despite the March incident. Persistent backorders could erode margin if production bottlenecks extend beyond the current quarter. SYK’s management noted that backorder processing is now back on track, which should help maintain revenue momentum. Keep an eye on any updates on supply‑chain capacity in the next earnings release, as delays could trigger a short‑term dip.
Frequently Asked Questions About SYK
Is Stryker Corporation (SYK) stock a good investment in 2026?
The bull case for Stryker hinges on its resilient revenue mix across MedSurg, Neurotechnology, and Orthopaedics, with Q2 2026 sales reaching $6.59 billion, a 9.4% year‑over‑year increase. Recent earnings showed EPS of $3.69 versus the $3.49 consensus, indicating solid profitability. The company’s dividend of $0.88 per share quarterly provides a modest yield, and its payout ratio remains within a sustainable range. Valuation sits at a forward P/E of 38.97, slightly below the peer average of 53.0, suggesting relative affordability. Risks include potential reimbursement changes and supply‑chain backorders that could temper growth. Overall, Stryker presents a balanced mix of growth prospects and dividend stability for 2026 investors.
What drives Stryker (SYK) stock price in the next quarter?
Short‑term catalysts for SYK include the Q3 2026 earnings announcement on September 20, where management is expected to detail full‑year guidance and cyber‑attack remediation progress. Analysts anticipate a 9% organic sales growth trajectory, which could support margin expansion. Additionally, any updates on reimbursement policy from the Centers for Medicare & Medicaid Services may influence revenue momentum. The company’s recent UBS target adjustment to $382 from $400 signals caution but also highlights potential upside if guidance remains positive. Watch for any supply‑chain backorder updates, as they could temporarily dampen earnings expectations.
Does Stryker Corporation (SYK) pay a dividend?
Yes, Stryker declares a quarterly dividend of $0.88 per share, translating to an annualized dividend of $3.52. This payout aligns with the company’s consistent dividend policy and reflects its stable cash‑flow generation. The dividend yield, based on the current price of $339.25, sits around 1.04%, offering a modest income stream. Stryker’s dividend quality is reinforced by its strong operating margins and free‑cash‑flow generation, which support ongoing payments. Investors can expect the dividend to remain unchanged unless significant capital‑expenditure needs arise.
What are the risks of buying Stryker (SYK) stock?
Key risks for SYK include potential reimbursement reductions from Medicare and private insurers, which could compress margins. The March 2026 cyber‑attack highlighted vulnerabilities in the company’s supply chain and IT infrastructure; any lingering disruptions might delay product launches. Competitive pressure from larger medical‑device firms, such as Medtronic and Abbott, could erode market share in orthopaedic implants. Additionally, the company’s high valuation relative to peers may limit upside if earnings growth stalls. Currency fluctuations could affect overseas sales, as Stryker operates in 75 countries. Finally, regulatory changes in the medical‑device sector could impose new compliance costs.
How has Stryker (SYK) performed this year?
Stryker’s stock returned 3.7% over the past month and 15.2% over the last three months, reflecting a recent rally. However, the year‑to‑date return is -6.0%, indicating a decline compared to the previous year. The 52‑week high of $396.86 and low of $281.00 show a 14.6% drop from the peak and a 20.6% rise from the trough, respectively. The current price of $339.25 places the stock roughly 14.6% below its 52‑week high. Market sentiment is rising, with a sentiment score of 70 and a 5‑point positive delta over the last 14 days. These metrics suggest a volatile but potentially opportunistic trading window.
What did Stryker (SYK) earn in Q2 2026?
In Q2 2026, Stryker reported EPS of $3.69, beating the analyst consensus of $3.49 by 0.20. Revenue reached $6.589 billion versus the $6.646 billion estimate, a 0.9% shortfall. The company highlighted a 9% organic sales growth and margin expansion, underscoring operational resilience. Compared to Q1 2026, EPS improved from $2.60 to $3.69, while revenue rose from $6.020 billion to $6.589 billion. These figures illustrate a rebound after a revenue dip in Q1 2026, driven by recovery from a March cyber‑attack. Analysts note that the company’s guidance will be pivotal for next quarter’s valuation.
What is Stryker’s revenue trend over the last four quarters?
Revenue has fluctuated over the past year: Q4 2025 was $7.171 billion, Q1 2026 dropped to $6.020 billion, and Q2 2026 rebounded to $6.589 billion. This pattern reflects a temporary decline followed by a 9% organic growth in Q2. The company’s revenue growth rate in Q2 2026 was 9% YoY, matching the 9% increase reported for Q2 2025. Despite the dip in Q1, the upward trajectory suggests a stabilizing trend. Monitoring the next earnings release will clarify whether the rebound continues into FY2026.
What is the analyst consensus on Stryker (SYK) stock?
Analysts currently target an average price of $382.04 for SYK, with a high range of $465.00 and a low of $315.00. The consensus is split among 28 buy, 6 hold, and no sell ratings. UBS recently reduced its target to $382 from $400, citing guidance caution. The mean target reflects a moderate upside potential if the company maintains its earnings beats. Investors should note the consensus range when evaluating valuation relative to the current price of $339.25.
What is Stryker’s dividend policy and payout ratio?
Stryker maintains a quarterly dividend of $0.88, translating to an annualized payout of $3.52 per share. The dividend yield, calculated on the current price of $339.25, stands at approximately 1.04%. The company’s payout ratio is moderate, balancing dividend payments with reinvestment in R&D and capital expenditures. Historically, Stryker has upheld its dividend even during revenue downturns, indicating a strong cash‑flow foundation. Dividend stability is a key factor for income‑focused investors.
How is Stryker’s valuation relative to its peers?
Stryker trades at a forward P/E of 38.97, which is below the peer average of 53.0, suggesting relative affordability. The 52‑week high of $396.86 and low of $281.00 place the stock 14.6% below its peak, indicating potential upside if the company sustains earnings growth. Analysts view the current price as moderately undervalued compared to the consensus target of $382.04. The valuation gap could widen if guidance remains positive and margins expand. However, a high valuation relative to peers also introduces downside risk if earnings falter.
What competitive advantages does Stryker (SYK) hold in the medical‑device market?
Stryker’s diversified product portfolio across MedSurg, Neurotechnology, and Orthopaedics provides cross‑segment resilience. Its orthopaedic implants command a strong market share in joint replacement and trauma, while its neurotechnology solutions are gaining traction in minimally invasive procedures. The company’s focus on innovation, as evidenced by recent product launches and R&D spending, fuels long‑term growth. Stryker’s global distribution network spans 75 countries, enhancing market reach. These factors collectively position SYK favorably against competitors such as Medtronic and Abbott.
When will Stryker (SYK) next report earnings?
Stryker’s Q3 2026 earnings are scheduled for release on September 20, 2026. Management is expected to discuss full‑year guidance, cyber‑attack remediation progress, and supply‑chain backorder status. Analysts are anticipating a 9% organic sales growth continuation, which could influence the stock’s short‑term trajectory. Investors should monitor the earnings call for updates on reimbursement policy changes and margin outlook. The release date offers a clear calendar event for investors tracking near‑term catalysts.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
